Symbols / TVRD Stock $3.10 +2.99% Tvardi Therapeutics, Inc.

Healthcare • Biotechnology • United States • NCM
TVRD (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO —
Exch · Country NCM · United States
Market Cap 29.08M
Enterprise Value -1.53M
Income -18.21M
Sales —
FCF (ttm) -15.22M
Book/sh 2.23
Cash/sh 3.28
Employees 12
Insider 10d —
IPO Jan 31, 2014
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -1.26
PEG —
P/S —
P/B 1.39
P/C —
EV/EBITDA 0.06
EV/Sales —
Quick Ratio 2.79
Current Ratio 2.86
Debt/Eq 0.96
LT Debt/Eq —
EPS (ttm) -3.26
EPS next Y -2.45
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-13
Earnings (prior) 2026-03-31
ROA -49.70%
ROE -237.81%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 9.38M
Shs Float 6.46M
Insider Own 34.64%
Instit Own 30.16%
Short Float 5.94%
Short Ratio 9.42
Short Interest 554.34K
52W High 43.65
vs 52W High -92.90%
52W Low 2.75
vs 52W Low 12.73%
Beta —
Impl. Vol. 1.63%
Rel Volume 0.42
Avg Volume 52.50K
Volume 22.16K
Target (mean) $8.17
Tgt Median $8.00
Tgt Low $3.00
Tgt High $15.00
# Analysts 6
Recom Buy
Prev Close $3.01
Price $3.10
Change 2.99%
About

Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$8.17
Mean price target
2. Current target
$3.10
Latest analyst target
3. DCF / Fair value
$-29.20
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.10
Low
$3.00
High
$15.00
Mean
$8.17

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-20 down Barclays Equal-Weight → Underweight $3
2026-04-01 main Barclays Equal-Weight → Equal-Weight $4
2026-04-01 main Piper Sandler Neutral → Neutral $3
2026-04-01 reit BTIG Buy → Buy $15
2025-10-14 down Raymond James Outperform → Market Perform —
2025-10-13 main BTIG Buy → Buy $15
2025-10-13 init Barclays — → Overweight $61
2025-07-14 init Raymond James — → Outperform $62
2025-07-11 init Cantor Fitzgerald — → Overweight $52
2025-06-12 init Piper Sandler — → Overweight $78
2025-05-21 init Oppenheimer — → Outperform $65
2025-04-28 init Jones Trading — → Buy $39
News
RSS: Latest TVRD news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-04-15 WIRK SHAHEEN Director — 4,191 $0.00 $0
2025-04-15 WIRK SHAHEEN Director — 439,194 $0.00 $0
2025-04-15 HALL WALLACE L JR Director — 246,756 $0.00 $0
2025-02-28 TERRILLION SCOTT M General Counsel — 163 $4.76 $776
2025-02-28 POSNER CHRISTOPHER Chief Executive Officer — 583 $4.75 $2,769
2025-02-04 POSNER CHRISTOPHER Chief Executive Officer — 372 $4.72 $1,756
2024-11-04 POSNER CHRISTOPHER Chief Executive Officer — 3,668 $0.29 $1,064
2024-08-01 POSNER CHRISTOPHER Chief Executive Officer — 4,149 $0.35 $1,452
2024-06-04 IVES JEFFREY L Director — 150,647 — —
2024-06-04 BOUDREAU HELEN M. Director — 150,647 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
26.75
-4.84%
28.11
+50.59%
18.66
-11.93%
21.19
Research And Development
18.01
-23.84%
23.65
+49.06%
15.87
-14.08%
18.47
Selling General And Administration
8.74
+96.03%
4.46
+59.24%
2.80
+2.64%
2.73
General And Administrative Expense
8.74
+96.03%
4.46
+59.24%
2.80
+2.64%
2.73
Other Gand A
8.74
+96.03%
4.46
+59.24%
2.80
+2.64%
2.73
Total Expenses
26.75
-4.84%
28.11
+50.59%
18.66
-11.93%
21.19
Operating Income
-26.75
+4.84%
-28.11
-50.59%
-18.66
+11.93%
-21.19
Total Operating Income As Reported
-26.75
+4.84%
-28.11
-50.59%
-18.66
+11.93%
-21.19
EBITDA
-26.65
+4.85%
-28.01
-62.37%
-17.25
+15.65%
-20.45
Normalized EBITDA
-26.65
+4.85%
-28.01
-62.37%
-17.25
+15.65%
-20.45
Reconciled Depreciation
0.10
+0.00%
0.10
+0.00%
0.10
+11.76%
0.09
EBIT
-26.75
+4.84%
-28.11
-62.03%
-17.35
+15.54%
-20.54
Net Income
-18.21
+38.04%
-29.40
-69.46%
-17.35
+15.55%
-20.54
Pretax Income
-18.21
+38.04%
-29.40
-69.46%
-17.35
+15.55%
-20.54
Net Non Operating Interest Income Expense
1.38
+84.07%
0.75
-43.32%
1.32
+102.46%
0.65
Interest Expense Non Operating
—
—
0.00
-100.00%
0.00
Net Interest Income
1.38
+84.07%
0.75
-43.32%
1.32
+102.46%
0.65
Interest Expense
—
—
0.00
-100.00%
0.00
Interest Income Non Operating
1.38
+84.07%
0.75
-43.32%
1.32
+101.53%
0.65
Interest Income
1.38
+84.07%
0.75
-43.32%
1.32
+101.53%
0.65
Other Income Expense
7.16
+451.45%
-2.04
—
—
Other Non Operating Income Expenses
7.16
+451.45%
-2.04
—
—
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-18.21
+38.04%
-29.40
-69.46%
-17.35
+15.55%
-20.54
Net Income From Continuing Operation Net Minority Interest
-18.21
+38.04%
-29.40
-69.46%
-17.35
+15.55%
-20.54
Net Income From Continuing And Discontinued Operation
-18.21
+38.04%
-29.40
-69.46%
-17.35
+15.55%
-20.54
Net Income Continuous Operations
-18.21
+38.04%
-29.40
-69.46%
-17.35
+15.55%
-20.54
Normalized Income
-18.21
+38.04%
-29.40
-69.46%
-17.35
+15.55%
-20.54
Net Income Common Stockholders
-18.21
+38.04%
-29.40
-69.46%
-17.35
+15.55%
-20.54
Diluted EPS
-3.26
-3.75%
-3.14
-69.46%
-1.85
+15.55%
-2.20
Basic EPS
-2.46
+21.71%
-3.14
-69.46%
-1.85
+15.55%
-2.20
Basic Average Shares
7.42
-20.70%
9.36
+0.00%
9.36
+0.00%
9.36
Diluted Average Shares
7.78
-16.81%
9.36
+0.00%
9.36
+0.00%
9.36
Diluted NI Availto Com Stockholders
-18.21
+38.04%
-29.40
-69.46%
-17.35
+15.55%
-20.54
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
32.07
-8.88%
35.20
+30.36%
27.00
-40.13%
45.10
Current Assets
31.54
-0.47%
31.69
+21.13%
26.16
-40.70%
44.11
Cash Cash Equivalents And Short Term Investments
30.81
-2.54%
31.61
+37.94%
22.92
-47.60%
43.74
Cash And Cash Equivalents
20.73
-34.42%
31.61
+37.94%
22.92
+6.65%
21.49
Other Short Term Investments
10.08
0.00
0.00
-100.00%
22.25
Prepaid Assets
0.73
+909.72%
0.07
-97.78%
3.24
+775.41%
0.37
Total Non Current Assets
0.54
-84.77%
3.51
+316.73%
0.84
-14.68%
0.99
Net PPE
0.20
-34.67%
0.30
-20.63%
0.38
-17.83%
0.46
Gross PPE
0.20
-34.67%
0.30
-20.63%
0.38
-17.83%
0.46
Other Properties
0.20
-34.67%
0.30
-20.63%
0.38
-17.83%
0.46
Goodwill And Other Intangible Assets
0.32
-16.36%
0.39
-14.06%
0.45
-12.33%
0.51
Other Intangible Assets
0.32
-16.36%
0.39
-14.06%
0.45
-12.33%
0.51
Non Current Deferred Assets
0.00
-100.00%
2.81
—
—
Other Non Current Assets
0.02
+0.00%
0.02
+0.00%
0.02
+0.00%
0.02
Total Liabilities Net Minority Interest
11.13
-91.19%
126.33
+41.85%
89.06
-1.21%
90.15
Current Liabilities
11.04
+6.51%
10.37
+215.97%
3.28
-23.29%
4.28
Payables And Accrued Expenses
9.63
+5.56%
9.12
+306.14%
2.25
-36.14%
3.52
Payables
3.22
+47.26%
2.19
+35.69%
1.61
-33.13%
2.41
Accounts Payable
3.22
+47.26%
2.19
+35.69%
1.61
-33.13%
2.41
Current Accrued Expenses
6.41
-7.58%
6.94
+992.28%
0.64
-42.69%
1.11
Pensionand Other Post Retirement Benefit Plans Current
1.30
+13.57%
1.14
+21.23%
0.94
+38.94%
0.68
Current Debt And Capital Lease Obligation
0.12
+12.62%
0.10
+10.75%
0.09
+13.41%
0.08
Current Capital Lease Obligation
0.12
+12.62%
0.10
+10.75%
0.09
+13.41%
0.08
Total Non Current Liabilities Net Minority Interest
0.09
-99.93%
115.96
+35.19%
85.78
-0.11%
85.87
Long Term Debt And Capital Lease Obligation
0.09
-99.72%
30.46
+10976.36%
0.28
-25.27%
0.37
Long Term Debt
—
30.26
—
—
Long Term Capital Lease Obligation
0.09
-57.71%
0.20
-26.91%
0.28
-25.27%
0.37
Preferred Securities Outside Stock Equity
0.00
-100.00%
85.50
+0.00%
85.50
+0.00%
85.50
Stockholders Equity
20.95
+122.98%
-91.13
-46.85%
-62.06
-37.75%
-45.05
Common Stock Equity
20.95
+122.98%
-91.13
-46.85%
-62.06
-37.75%
-45.05
Capital Stock
0.01
+350.00%
0.00
-89.47%
0.02
+0.00%
0.02
Common Stock
0.01
+350.00%
0.00
-89.47%
0.02
+0.00%
0.02
Share Issued
9.38
+0.28%
9.36
+0.00%
9.36
+0.00%
9.36
Ordinary Shares Number
9.38
+0.28%
9.36
+0.00%
9.36
+0.00%
9.36
Additional Paid In Capital
131.38
+11811.06%
1.10
+44.75%
0.76
+70.85%
0.45
Retained Earnings
-110.45
-19.75%
-92.24
-46.78%
-62.84
-38.13%
-45.49
Gains Losses Not Affecting Retained Earnings
0.01
0.00
0.00
+100.00%
-0.02
Other Equity Adjustments
0.01
—
—
-0.02
Total Equity Gross Minority Interest
20.95
+122.98%
-91.13
-46.85%
-62.06
-37.75%
-45.05
Total Capitalization
20.95
+134.41%
-60.87
+1.91%
-62.06
-37.75%
-45.05
Working Capital
20.50
-3.86%
21.32
-6.81%
22.88
-42.57%
39.83
Invested Capital
20.95
+134.41%
-60.87
+1.91%
-62.06
-37.75%
-45.05
Total Debt
0.20
-99.34%
30.56
+8205.16%
0.37
-18.22%
0.45
Capital Lease Obligations
0.20
-33.88%
0.30
-17.39%
0.37
-18.22%
0.45
Net Tangible Assets
20.62
+122.54%
-91.52
-46.41%
-62.51
-37.19%
-45.56
Tangible Book Value
20.62
+122.54%
-91.52
-46.41%
-62.51
-37.19%
-45.56
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-23.50
-28.37%
-18.30
+13.00%
-21.04
-17.77%
-17.87
Cash Flow From Continuing Operating Activities
-23.50
-28.37%
-18.30
+13.00%
-21.04
-17.77%
-17.87
Net Income From Continuing Operations
-18.21
+38.04%
-29.40
-69.46%
-17.35
+15.55%
-20.54
Depreciation Amortization Depletion
0.10
+0.00%
0.10
+0.00%
0.10
+11.76%
0.09
Depreciation And Amortization
0.10
+0.00%
0.10
+0.00%
0.10
+11.76%
0.09
Other Non Cash Items
0.72
+214.35%
0.23
+350.98%
0.05
+50.00%
0.03
Stock Based Compensation
1.40
+338.56%
0.32
+1.59%
0.31
+27.64%
0.25
Unrealized Gain Loss On Investment Securities
-7.81
-532.21%
1.81
—
—
Change In Working Capital
0.51
-94.12%
8.64
+318.26%
-3.96
-248.50%
2.67
Change In Prepaid Assets
-0.31
-109.73%
3.17
+210.39%
-2.87
-700.21%
0.48
Change In Payables And Accrued Expense
0.92
-83.49%
5.57
+652.28%
-1.01
-145.92%
2.19
Change In Other Current Liabilities
-0.10
-10.75%
-0.09
-13.41%
-0.08
-1071.43%
-0.01
Investing Cash Flow
-10.08
0.00
-100.00%
22.47
+202.13%
-22.00
Cash Flow From Continuing Investing Activities
-10.08
0.00
-100.00%
22.47
+202.13%
-22.00
Net PPE Purchase And Sale
—
—
0.00
+100.00%
-0.05
Purchase Of PPE
—
—
0.00
+100.00%
-0.05
Capital Expenditure
—
—
—
-0.05
Net Investment Purchase And Sale
-10.08
0.00
-100.00%
22.47
+202.36%
-21.95
Purchase Of Investment
-31.49
0.00
0.00
+100.00%
-43.99
Sale Of Investment
21.40
0.00
-100.00%
22.47
+1.92%
22.05
Financing Cash Flow
22.70
-15.91%
27.00
+1349900.00%
0.00
-50.00%
0.00
Cash Flow From Continuing Financing Activities
22.70
-15.91%
27.00
+1349900.00%
0.00
-50.00%
0.00
Net Issuance Payments Of Debt
0.00
-100.00%
28.30
—
—
Issuance Of Debt
0.00
-100.00%
28.30
—
—
Long Term Debt Issuance
0.00
-100.00%
28.30
—
—
Net Long Term Debt Issuance
0.00
-100.00%
28.30
—
—
Net Common Stock Issuance
0.53
+10540.00%
0.01
+150.00%
0.00
-50.00%
0.00
Net Other Financing Charges
22.17
+1801.53%
-1.30
—
—
Changes In Cash
-10.88
-225.13%
8.70
+508.04%
1.43
+103.59%
-39.86
Beginning Cash Position
31.61
+37.94%
22.92
+6.65%
21.49
-64.97%
61.35
End Cash Position
20.73
-34.42%
31.61
+37.94%
22.92
+6.65%
21.49
Free Cash Flow
-23.50
-28.37%
-18.30
+13.00%
-21.04
-17.44%
-17.92
Amortization Of Securities
-0.20
0.00
+100.00%
-0.19
+45.35%
-0.35
Common Stock Issuance
0.53
+10540.00%
0.01
+150.00%
0.00
-50.00%
0.00
Issuance Of Capital Stock
0.53
+10540.00%
0.01
+150.00%
0.00
-50.00%
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category